Invention gives improved gene technology analysis

Apr 24, 2008

A patent for a system that gives more reliable results in gene technology-based diagnostic tests has been granted to researchers at the Norwegian Institute of Public Health (NIPH).

Gene technology analysis is used increasingly in diagnostic tests for detection of minute amounts of cells, bacteria and viruses in biological samples. However, false positive or negative results may occur.

- To uncover false negative results, an internal control reagent can be included in the tests to verify that the analysis results are valid. The problem with the internal controls used in today’s analyses is that they can only be added during, or at the end of the analysis process. This means that quality assurance is incomplete, explains Einar Sverre Berg at the Department for Virology.

Together with colleague Kjell Skaug he invented a protective shell for the internal control, based on cell/virus-mimicking liposomes. The liposome/internal control particles can thus be mixed with the biological test material when the sample is taken and be present during the entire analytical process. Whole process quality assurance is thereby achieved with more reliable results.

Chlamydia test first

Berg and Skaug were among the first in the world to show that restrictive substances in urine samples are an important source of false negative results in gene technology-based chlamydia tests.

The scientists recognised the problem with incomplete quality assurance, and invented the solution for the tests.

- A fantastic property of the system is that it isn’t limited to just one test. It can be used in any gene technology-based assay detecting biologically substances. The liposome can be tailored and adapted according to the target – be it a virus or bacterium. The potential, in other words, is enormous, says Berg.

Berg and his colleague have applied for a patent on their discovery in all industrialised countries and have established the company IC Particles AS. Patents were first granted in New Zealand and Australia, followed by Norway. Berg is also optimistic about getting a patent in the USA within this year.

- Without the NIPH’s goodwill and patience it is likely that the IC Particle’s invention would not have been developed, concludes Einar Sverre Berg.

Source: Norwegian Institute of Public Health

Explore further: Aging white lion euthanized at Ohio zoo

add to favorites email to friend print save as pdf

Related Stories

Sampling rivers for genes rather than organisms

Dec 11, 2014

Effective environmental management depends on a detailed knowledge of the distribution of species. But taxonomists are in short supply, and some species can be difficult to identify, even for experts. Eawag, ...

Scientists find key to vitamin A metabolism

Dec 10, 2014

Researchers at Case Western Reserve University School of Medicine have uncovered the mechanism that enables the enzyme Lecithin: retinol acyltransferase (LRAT) to store vitamin A—a process that is indispensable ...

Discovery links shift in metabolism to stem cell renewal

Dec 10, 2014

Stem cells in early embryos have unlimited potential; they can become any type of cell, and researchers hope to one day harness this rejuvenating power to heal disease and injury. To do so, they must, among ...

Recommended for you

A vegetarian carnivorous plant

Dec 19, 2014

Carnivorous plants catch and digest tiny animals in order and derive benefits for their nutrition. Interestingly the trend towards vegetarianism seems to overcome carnivorous plants as well. The aquatic carnivorous bladderwort, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.